LivaNova (NASDAQ:LIVN) Updates FY 2026 Earnings Guidance

LivaNova (NASDAQ:LIVN) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 4.300-4.400 for the period, compared to the consensus earnings per share estimate of 4.150. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on LIVN shares. Barclays boosted their price objective on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Freedom Capital upgraded LivaNova to a “hold” rating in a report on Tuesday, June 30th. Zacks Research raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Weiss Ratings upgraded LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Finally, KeyCorp raised their price objective on shares of LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Monday, June 22nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $82.88.

LivaNova Stock Performance

NASDAQ LIVN traded down $8.64 during midday trading on Wednesday, hitting $76.68. The company had a trading volume of 1,081,424 shares, compared to its average volume of 772,182. The firm has a fifty day simple moving average of $79.46 and a two-hundred day simple moving average of $70.51. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. LivaNova has a fifty-two week low of $45.64 and a fifty-two week high of $85.76. The stock has a market cap of $4.21 billion, a price-to-earnings ratio of 39.28 and a beta of 0.86.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, August 5th. The company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.09 by $0.17. The firm had revenue of $390.59 million during the quarter, compared to analysts’ expectations of $380.50 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.LivaNova’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period last year, the business earned $1.05 earnings per share. LivaNova has set its FY 2026 guidance at 4.300-4.400 EPS. Equities analysts forecast that LivaNova will post 3.73 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Francesco Bianchi sold 1,800 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the sale, the director owned 7,228 shares of the company’s stock, valued at approximately $547,521. This represents a 19.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.35% of the company’s stock.

More LivaNova News

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q2 earnings and revenue beat estimates. LivaNova reported adjusted earnings of $1.26 per share, above the $1.08-$1.09 analyst consensus and up from $1.05 a year earlier. Revenue rose 10.8% year over year to $390.54 million, exceeding expectations of approximately $380.50 million. LivaNova Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management raised its full-year earnings outlook. FY 2026 EPS guidance was set at $4.30-$4.40, above the $4.15 consensus estimate. Revenue guidance of roughly $1.5 billion was maintained in line with analyst expectations. LivaNova exceeds second-quarter forecasts and increases 2026 outlook
• Neutral Sentiment: The shares recently hit a fresh 52-week high. The strong rally leading into the earnings announcement may have raised investor expectations and increased the potential for profit-taking, even after the earnings beat. LivaNova Hits Fresh High
• Negative Sentiment: Valuation may be contributing to the weaker reaction. With LivaNova trading near its yearly high and at approximately 38.6 times earnings, investors may be demanding stronger guidance or additional upside beyond the reported beats. The revenue outlook was merely in line with consensus, which may have limited enthusiasm.

Hedge Funds Weigh In On LivaNova

A number of institutional investors have recently modified their holdings of the stock. Corient Private Wealth LLC bought a new position in LivaNova in the 4th quarter worth approximately $302,000. Pacer Advisors Inc. boosted its stake in shares of LivaNova by 131.7% in the 4th quarter. Pacer Advisors Inc. now owns 16,661 shares of the company’s stock valued at $1,025,000 after purchasing an additional 9,471 shares during the last quarter. Invesco Ltd. raised its stake in shares of LivaNova by 4.5% during the fourth quarter. Invesco Ltd. now owns 1,091,086 shares of the company’s stock worth $67,135,000 after buying an additional 47,323 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in LivaNova during the 4th quarter worth $306,000. Finally, State of Tennessee Department of Treasury lifted its stake in shares of LivaNova by 44.9% in the 4th quarter. State of Tennessee Department of Treasury now owns 30,304 shares of the company’s stock valued at $1,991,000 after purchasing an additional 9,396 shares during the period. 97.64% of the stock is owned by institutional investors.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.